Photography
fromFast Company
11 hours agoEli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Eli Lilly has signed a $1.3 billion deal with Superluminal Medicines to develop AI-driven drugs targeting obesity and cardiometabolic diseases.